Discussion about this post

User's avatar
Mary Braun Bates, MD's avatar

If finerenone decreased the risk of hyperkalemia, that could be worthwhile, even if the outcomes were the same. For a frail patient whose children have to take time off from work to take them to the lab for their blood draws, less fussing about the potassium is a plus. The study indicates a slight bump compared to placebo. The real comparison I want, of course, is to spironolactone.

Expand full comment
Benjamin Hourani's avatar

All that is new is not necessarily better, but all it is new is always much more expensive.

I will continue to use spiirolactone until unacceptable side effects occur and only then switch.

Ben Hourani , MD, MBA

Expand full comment
12 more comments...

No posts